Natural killer cell biology and its effect on graft versus host disease
Archives of Medical Laboratory Sciences,
Vol. 3 No. 4 (2017),
26 September 2018
https://doi.org/10.22037/amls.v3i4.20365
Abstract
Natural killer (NK) cells were originally described in terms of their function. NK cells are of lymphoid origin and are found in the peripheral blood, spleen, and bone marrow, as well as other tissues. These cells are large, radio-resistant and granular lymphocytes that represent an important arm of innate immunity and are thought to play a critical role in the immune surveillance against tumors and virally infected cells. Allogeneic bone marrow transplantation (BMT) has proven to be an effective treatment for hematologic malignancies and some solid tumors. One of the major challenges of allo-stem cell transplantation (SCT) is to reduce the incidence and severity of GVHD while boosting the graft-versus-leukemia (GVL) effect. In the setting of allo-SCT, the reconstitution of NK cells is of notable interest due to their known capability to induce GVL without GVHD. Clinical applications of NK cells have been inspired by recognition of their potent anticancer activity. These studies discussed a solid basis for development of future NK cell trials for cancer therapy by minimizing risks and toxicities.
- Natural killer cell
- bone marrow transplantation
- graft versus host disease
- graft versus leukemia
How to Cite
References
References
Hallett W, Murphy WJ. Natural killer cells: biology and clinical use in cancer therapy. Cell Mol Immunol. 2004;1(1):12-21.
Caligiuri MA. Human natural killer cells. Blood. 2008;112(3):461-9.
Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood reviews. 2006;20(3):123-37.
Moretta L, Ciccone E, Mingari MC, Biassoni R, Moretta A. Human natural killer cells: origin, clonality, specificity, and receptors. Advances in immunology. 55: Elsevier; 1993. p. 341-80.
Hofer E, Koehl U. Natural Killer cell-Based cancer immunotherapies: From immune evasion to Promising targeted cellular therapies. Frontiers in immunology. 2017;8:745.
Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature. 2000;408(6808):57.
Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331(6013):44-9.
Wagtmann N, Biassoni R, Cantoni C, Verdiani S, Malnati MS, Vitale M, et al. Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra-and intracellular domains. Immunity. 1995;2(5):439-49.
Pende D, Biassoni R, Cantoni C, Verdiani S, Falco M, Di Donato C, et al. The natural killer cell receptor specific for HLA-A allotypes: a novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimer. Journal of Experimental Medicine. 1996;184(2):505-18.
Braud VM, Allan DS, O'callaghan CA, Söderström K, D'andrea A, Ogg GS, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998;391(6669):795.
Bouteiller P, Blaschitz A. The functionality of HLA‐G is emerging. Immunological reviews. 1999;167(1):233-44.
Steinle A, Li P, Morris DL, Groh V, Lanier LL, Strong RK, et al. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Immunogenetics. 2001;53(4):279-87.
Cosman D, Müllberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, et al. ULBPs, novel MHC class I–related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001;14(2):123-33.
Lanier L, Ruitenberg J, Phillips J. Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes. The Journal of Immunology. 1988;141(10):3478-85.
Walker JA, Barlow JL, McKenzie AN. Innate lymphoid cells—how did we miss them? Nature reviews immunology. 2013;13(2):75.
Copelan EA. Hematopoietic stem-cell transplantation. New England Journal of Medicine. 2006;354(17):1813-26.
Olson JA, Leveson-Gower DB, Gill S, Baker J, Beilhack A, Negrin RS. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood. 2010;115(21):4293-301.
Murphy WJ, Bennett M, Kumar V, Longo DL. Donor-type activated natural killer cells promote marrow engraftment and B cell development during allogeneic bone marrow transplantation. The Journal of Immunology. 1992;148(9):2953-60.
Lopez C, Sorell M, Kirkpatrick D, O'Reilly R, Ching C. Association between pre-transplant natural kill and graft-versus-host disease after stem-cell transplantation. The Lancet. 1979;314(8152):1103-7.
Jacobs B, Tognarelli S, Poller K, Bader P, Mackensen A, Ullrich E. NK cell subgroups, phenotype, and functions after autologous stem cell transplantation. Frontiers in immunology. 2015;6:583.
Bertuccio SN, Serravalle S, Astolfi A, Lonetti A, Indio V, Leszl A, et al. Identification of a cytogenetic and molecular subgroup of acute myeloid leukemias showing sensitivity to L-Asparaginase. Oncotarget. 2017;8(66):109915.
Lowdell M. Natural killer cells in haematopoietic stem cell transplantation. Transfusion Medicine. 2003;13(6):399-404.
Rivas MN, Hazzan M, Weatherly K, Gaudray F, Salmon I, Braun MY. NK cell regulation of CD4 T cell-mediated graft-versus-host disease. The Journal of immunology. 2010;184(12):6790-8.
Larghero J, Rocha V, Porcher R, Filion A, Ternaux B, Lacassagne MN, et al. Association of bone marrow natural killer cell dose with neutrophil recovery and chronic graft‐versus‐host disease after HLA identical sibling bone marrow transplants. British journal of haematology. 2007;138(1):101-9.
Ming-Yi H, Tang S-J, Kuang-Hui S, Yang W. Immunotherapy for Lung Cancers. BioMed Research International. 2011.
Piccioli D, Sbrana S, Melandri E, Valiante NM. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. Journal of Experimental Medicine. 2002;195(3):335-41.
Rabinovich BA, Li J, Shannon J, Hurren R, Chalupny J, Cosman D, et al. Activated, but not resting, T cells can be recognized and killed by syngeneic NK cells. The Journal of Immunology. 2003;170(7):3572-6.
Cerboni C, Zingoni A, Cippitelli M, Piccoli M, Frati L, Santoni A. Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK-cell lysis. Blood. 2007;110(2):606-15.
McNerney M, Lee KM, Zhou P, Molinero L, Mashayekhi M, Guzior D, et al. Role of natural killer cell subsets in cardiac allograft rejection. American journal of transplantation. 2006;6(3):505-13.
Simonetta F, Alvarez M, Negrin RS. Natural killer cells in graft-versus-host-disease after allogeneic hematopoietic cell transplantation. Frontiers in immunology. 2017;8:465.
Nalle SC, Kwak HA, Edelblum KL, Joseph NE, Singh G, Khramtsova GF, et al. Recipient NK cell inactivation and intestinal barrier loss are required for MHC-matched graft-versus-host disease. Science translational medicine. 2014;6(243):243ra87-ra87.
Xun C, Brown SA, Jennings CD, Henslee-Downey PJ, Thompson JS. Acute graft-versus-host-like disease induced by transplantation of human activated natural killer cells into SCID mice. Transplantation. 1993;56(2):409-17.
Xun CQ, Thompson JS, Jennings CD, Brown SA. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells. Transplantation. 1995;60(8):821-7.
Peng H, Tian Z. Natural killer cell memory: progress and implications. Frontiers in immunology. 2017;8:1143.
O’Sullivan TE, Sun JC, Lanier LL. Natural killer cell memory. Immunity. 2015;43(4):634-45.
O'Leary JG, Goodarzi M, Drayton DL, von Andrian UH. T cell–and B cell–independent adaptive immunity mediated by natural killer cells. Nature immunology. 2006;7(5):507.
Koprivnikar J, McCloskey J, Faderl S. Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia. OncoTargets and therapy. 2017;10:1413.
Szoor A, Velasquez MP, Bonifant CL, Vaidya A, Brunetti L, Gundry M, et al. Two-pronged Cell Therapy: Engineering NK cells to target CD22 and redirect bystander T cells to CD19 for the adoptive immunotherapy of B-cell malignancies. Am Assoc Immnol; 2017.
Boissel L, Betancur M, Wels WS, Tuncer H, Klingemann H. Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leukemia research. 2009;33(9):1255-9.
Hoseini S, Cheung N. Acute myeloid leukemia targets for bispecific antibodies. Blood cancer journal. 2017;7(2):e522.
Rezvani K, Rouce R, Liu E, Shpall E. Engineering natural killer cells for cancer immunotherapy. Molecular Therapy. 2017;25(8):1769-81.
Secchiari F, Iastrebner M, Nuñez S, Tamashiro M, Torres N, Sierra J, et al. Expression of Ligands of the Activating Receptor NKG2D in Myelodysplastic Syndrome and Acute Myelogenous Leukemia Blasts and Lymphoid Cells. Leukemia Research. 2017;55:S123.
Nguyen R, Houston J, Chan WK, Finkelstein D, Dyer MA. The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma. Cancer Immunology, Immunotherapy. 2018:1-12.
Acheampong DO, Adokoh CK, Asante D-B, Asiamah EA, Barnie PA, Bonsu DO, et al. Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy. Biomedicine & Pharmacotherapy. 2018;97:225-32.
Boyiadzis M, Agha M, Redner RL, Sehgal A, Im A, Hou J-Z, et al. Phase 1 clinical trial of adoptive immunotherapy using “off-the-shelf” activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia. Cytotherapy. 2017;19(10):1225-32.
Bernson E, Hallner A, Sander F, Wilsson O, Werlenius O, Rydström A, et al. Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia. Leukemia. 2017;31(12):2552.
Cappuzzello E, Sommaggio R, Zanovello P, Rosato A. Cytokines for the induction of antitumor effectors: The paradigm of Cytokine-Induced Killer (CIK) cells. Cytokine & growth factor reviews. 2017;36:99-105.
Grimm EA, Mazumder A, Zhang H, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. Journal of Experimental Medicine. 1982;155(6):1823-41.
Trinchieri G, Matsumoto-Kobayashi M, Clark S, Seehra J, London L, Perussia B. Response of resting human peripheral blood natural killer cells to interleukin 2. Journal of Experimental Medicine. 1984;160(4):1147-69.
Casado JG, Tarazona R, Sanchez-Margallo F. NK and MSCs crosstalk: the sense of immunomodulation and their sensitivity. Stem Cell Reviews and Reports. 2013;9(2):184-9.
Galland S, Vuille J, Martin P, Letovanec I, Caignard A, Fregni G, et al. Tumor-Derived Mesenchymal Stem Cells Use Distinct Mechanisms to Block the Activity of Natural Killer Cell Subsets. Cell reports. 2017;20(12):2891-905.
Qi K, Li N, Zhang Z, Melino G. Tissue regeneration: The crosstalk between mesenchymal stem cells and immune response. Cellular immunology. 2017.
Amiri F, Halabian R, Salimian M, Shokrgozar MA, Soleimani M, Jahanian-Najafabadi A, et al. Induction of multipotency in umbilical cord-derived mesenchymal stem cells cultivated under suspension conditions. Cell Stress and Chaperones. 2014;19(5):657-66.
Volarevic V, Gazdic M, Simovic Markovic B, Jovicic N, Djonov V, Arsenijevic N. Mesenchymal stem cell‐derived factors: Immuno‐modulatory effects and therapeutic potential. Biofactors. 2017.
Davis ZB, Felices M, Verneris MR, Miller JS. Natural killer cell adoptive transfer therapy: exploiting the first line of defense against cancer. Cancer journal (Sudbury, Mass). 2015;21(6):486.
Rahim F, Saki N, Mousavi SH, Soleimani M, Khamisipour G. A review of biology and clinical use of mesenchymal stem cell: an immune-modulator progenitor cell. Apadana Journal of Clinical Research. 2012;1(1):3-16.
Ayello J, Hochberg J, Flower A, Chu Y, Baxi LV, Quish W, et al. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: potential for adoptive cellular immunotherapy. Experimental hematology. 2017;46:38-47.
Wikner E, Powell AB, Bollard CM, Cruz CR. Evaluating Expansion Protocols for Generating Cord Blood Derived Natural Killer Cell Therapies. 2017.
Williams BA, Law AD, Routy B. A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy. Oncotarget. 2017;8(51):89256.
Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, Pasquini R, et al. Outcome of cord-blood transplantation from related and unrelated donors. New England Journal of Medicine. 1997;337(6):373-81.
Gröschel C, Hübscher D, Nolte J, Monecke S, Sasse A, Elsner L, et al. Efficient killing of murine pluripotent stem cells by natural killer (NK) cells requires activation by cytokines and partly depends on the activating NK receptor NKG2D. Frontiers in immunology. 2017;8:870.
- Abstract Viewed: 240 times
- PDF Downloaded: 136 times